Efficacy and tolerability of artichoke dry extract (drug/extract ratio 25-35:1, aquous extract, CY450) as coated tablets containing 450 mg extract (tradename: Valverde Artischocke bei Verdauungsbeschwerden) was investigated in the treatment of hyperlipoproteinemia and compared with placebo. 143 adult patients with initial total cholesterol of > 7.3 mmol/l (> 280 mg/dl) were included in a double blind, randomized, placebo controlled, multi-center clinical trial. Patients received 1,800 mg artichoke dry extract per day or placebo over 6 weeks. Changes of total cholesterol and LDL-cholesterol from baseline to the end of treatment showed a statistically significant superiority (p = 0.0001) of artichoke dry extract over placebo. The decrease of total cholesterol in the CY450 group was 18.5% compared to 8.6% in the placebo group. LDL-cholesterol decrease in the CY450 group was 22.9% and 6.3% for placebo. LDL/HDL ratio showed a decrease of 20.2% in the CY450 group and 7.2% in the placebo group. There were no drug related adverse events during this study indicating an excellent tolerability of artichoke dry extract. This prospective study could contribute clear evidence to recommend artichoke dry extract CY450 for treating hyperlipoproteinemia and, thus, prevention of atherosclerosis and coronary heart disease.

30 min results in a marked binding of the ligand by a KCI-soluble nuclear extract. With both the cytosol and nuclear preparations the binding has specificity and a low dissociation constant (3 X 10-9 M). In addition the labeling of the nuclear preparation exhibits a saturation at approximately 7 X 10-10 M which probably reflects the molar concentration of cytoplasmic receptors.

No abstract

lnokosteron-26-oic acid was coupled to thyroglobulin in aqueous pyridine by a watersoluble carbodiimide. After exhaustive dialysis and gel filtration on Sephadex G-25 in the presence of sodium dodecylsulfate. a coupling ratio of 164 haptens per molecule of thyroglobulin was determined. In all three animals injected with the conjugate, ecdysone-binding antibodies were detected. After one booster injection the antiserum could be diluted 1:5 000 (1 r4000, or 1:2000) in order to get a 50% binding of [ 3 H]ecdysone. The dissociation constant was calculated as 5.8 10~1 0 mol//. The antiserum has a greater affinity for ecdysone and 22-isoecdysone than for all other ecdysteroids and steroids tested. £7/7 Radioimmuntest für Häutungshormone von Arthropoden, Einführung einer neuen Methode der immunogenen KopplungZusammenfassung: lnokosteron-26-säure wurde in wäßriger Pyridinlösung mit einem wasserlösli-chen Carbodiimid an Thyroglobulin gekoppelt. Die Kopplungsrate betrug 164 Haptene pro Molekül Thyroglobulin. Alle 3 immunisierten Kaninchen bildeten Antikörper gegen das Konjugat. Nach einer booster-Injektion konnte das Serum l: 5 000 (l: 4 000, bzw. l: 2 000) verdünnt werden, um 50% Bindung von [ 3 H]Ecdyson zu erhalten. Die Dissoziationskonstante beträgt 5.8 10~1 0 mol//. Das Antiserum hat eine größe-re Affinität für Ecdyson und 22-Iso-Ecdyson als für alle anderen getesteten Ecdysteroide und Steroide.

No abstract